Skip to content

ACAD ACADIA PHARMACEUTICALS INC

Follow

COM (common), issuer CIK 1070494

Filings received so far for Q3 2026: 10 13F filers report a position in ACAD shares at 2026-09-30. The quarter is not complete: its 13F deadline is 2026-11-14, and the counts grow as filings arrive.

13D and 13G filers

No 13D or 13G on this security in the data. Structured 13D/G data starts 2024-12-18.

Insider trades

No Form 4 transaction on this security in the data.

13F holders, Q3 2026

Filers in the available 13F reports with a share position at 2026-09-30, filer groups collapsed to one row (method), largest first. Options and principal amounts are left out. A group row states no % of portfolio, since each member reports its own portfolio: the members' percents are listed under it. A value about 1,000 times or 1/1,000 of the price other filers imply is shown as filed but neither ranks the row nor enters a sum.

HolderSharesValue% of portfolioChangeSource
Gradient Investments LLCin group Gradient Investments LLC31,593$637K0.01%-1,14513F-HRTimelineGroup
Valeo Financial Advisors, LLC21,033$424K0.01%new13F-HRTimeline
Farther Finance Advisors, LLC9,023$182K<0.01%+8,20013F-HRTimeline
GAMMA Investing LLC4,064$81.9K<0.01%+1,07913F-HRTimeline
Versant Capital Management, Inc974$19.6K<0.01%+3813F-HRTimeline
Grove Bank & Trust200$4.03K<0.01%013F-HRTimeline
MassMutual Private Wealth & Trust, FSB62$1.25K<0.01%013F-HRTimeline
Marquette Asset Management, LLC42$847<0.01%013F-HRTimeline
GILPIN WEALTH MANAGEMENT, LLC19$383<0.01%013F-HRTimeline
Davis Capital Management12$242<0.01%+513F-HRTimeline